Please assess the completion status of the following clinical trial:

Trial Title: EUS-guided CGN for Inoperable Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients ≥ 18 years old with cytology or histology confirmed pancreatic cancer, or radiologically suggestive of pancreatic cancer ( for patients whom biopsy is impossible)~2. Pain associated with inoperable cancer ( including abdominal pain or back pain, managed according to WHO analgesic ladder, with VAS score ≥4 despite simple analgesics (first 2 steps of WHO analgesic ladder)~3. Inoperability of cancer as demonstrated by EUS, computed tomography (CT) or Positive emission tomography~4. Informed consent available~Exclusion Criteria:~1. Unable to safely undergo EUS for any reason~2. Patient is unable to lie prone for procedure~3. Coagulopathy (prolongation of prothrombin time \> 18 sec) or thrombocytopenia \<80,000 platelets/ml)~4. Previous CPN or other neurolytic block that could affect pancreatic cancer-related pain or had implanted epidural or intrathecal analgesic therapy~5. Another cause for abdominal pain such as pseudocyst, ulcer or other intra-abdominal disorder~6. Allergy to local anaesthesia, contrast, or alcohol~7. Potential patient noncompliance (refusing to follow schedule of events)~8. Active alcohol or other drug use or significant psychiatric illness~9. Expected survival less than 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EUS-guided celiac ganglion neurolysis (Type: ACTIVE_COMPARATOR): Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
- Percutaneous celiac plexus neurolysis (Type: ACTIVE_COMPARATOR): Percutaneous celiac plexus neurolysis would be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).